| [1] |
Molton JS, Tambyah PA, Ang BS, et al. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia[J].Clin Infect Dis,2013,56(9):1310-1318.
|
| [2] |
Nordmann P,Poirel L,Walsh TR,et al.The emerging NDM carbapenemases[J].Trends Microbiol,2011,19(12):588-595.
|
| [3] |
Dortet L,Nordmann P,Poirel L.Association of the emerging carbapenemase NDM-1 with a bleomycin resistance protein in Enterobacteriaceae and Acinetobacter baumannii[J].Antimicrob Agents Chemother,2012,56(4):1693-1697.
|
| [4] |
Tangden T,Giske CG.Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae:clinical perspectives on detection,treatment and infection control[J].J Intern Med,2015,277(5):501-512.
|
| [5] |
Wailan AM,Paterson DL.The spread and acquisition of NDM-1: a multifactorial problem[J].Expert Rev Anti Infect Ther,2014,12(1):91-115.
|
| [6] |
Jin L,Bai XW,Luan N,et al.A Designed tryptophan- and lysine/arginine-rich antimicrobial peptide with therapeutic potential for clinical antibiotic-resistant Candida albicans Vaginitis[J].J Med Chem,2016,59(5):1791-1799.
|
| [7] |
Li B,Li B,Tian YW,et al.The anti-biofilm activity against drug-resistance bacterial of antimicrobial peptide BF-30 in vitro[J].Pharm Biotechnol,2015,22(1):14-19.
|
| [8] |
Li SA,Lee WH,Zhang Y.Efficacy of OH-CATH30 and its analogs against drug-resistant bacteria in vitro and in mouse models[J].Antimicrob Agents Chemother,2012,56(6):3309-3317.
|
| [9] |
Ma LM,Wang YR,Wang MX,et al.Effective antimicrobial activity of Cbf-14,derived from a cathelin-like domain,against penicillin-resistant bacteria[J].Biomaterials,2016,87:32-45.
|
| [10] |
Hao QR,Wang H,Wang J,et al.Effective antimicrobial activity of Cbf-K16 and Cbf-A7A13 against NDM-1-carrying Escherichia coli by DNA binding after penetrating thecytoplasmic membrane in vitro[J].J Pept Sci,2013,19(3):173-180.
|
| [11] |
Butt TR,Edavettal SC,Hall JP,et al.SUMO fusion technology for difficult-to-express proteins[J].Prot Exp Purif,2005,43(1):1-9.
|
| [12] |
Giles FJ,Rodriguez R,Weisdorf D,et al.A phase III,randomized,double-blind,placebo-controlled,study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy[J].Leukemia Res,2004,28(6):559-565.
|
| [13] |
Machuca J,Ortiz M,Recacha E,et al.Impact of AAC(6′)-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli[J].J Antimicrob Chemother,2016,71(11):3066-3071.
|
| [14] |
Fomda BA,Khan A,Zahoor D.NDM-1(New Delhi metallo beta lactamase-1)producing gram-negative bacilli: emergence & clinical implications[J].Indian J Med Res,2014,140(5):672-678.
|
| [15] |
Fan HY,Nazari M,Raval G,et al.Utilizing zeta potential measurements to study the effective charge,membrane partitioning,and membrane permeation of the lipopeptide surfactin[J].Biochim Biophys Acta,2014,1838(9):2306-2312.
|
| [16] |
Yuan Q,He L,Ke H.A potential substrate binding conformation of β-lactams and insight into the broad spectrum of NDM-1activity[J].Antimicrob Agents Chemother,2012,56(10):5157-5163.
|
| [17] |
Brogden KA.Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria[J].Nat Rev Microbiol,2005,3(3):238-250.
|
| [18] |
Oren Z,Shai Y.Mode of action of linear amphipathic α-helical antimicrobial peptides[J].Pept Sci,1998,47(6):451-463.
|
下载:
